ZyVersa Therapeutics Announces Article Published in Metabolism Pointing to Glomerular Cholesterol Accumulation as Key Factor Exacerbating Renal Injury and Dysfunction in Diabetic Kidney Disease
May 15, 2023 09:07 ET
|
ZyVersa Therapeutics
Published data demonstrate that a deficiency in cholesterol transporter ABCA1 increases deposition of cellular cholesterol, contributing to inflammation, cell death (apoptosis), and damage to the...
Panoramic Health Launches Clinical Research Division to Drive Discovery of Novel Kidney Disease Therapies
October 26, 2022 08:00 ET
|
Panoramic Health
TEMPE, Ariz., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Today, Panoramic Health℠, the nation's leading integrated value-based kidney care platform, announced the launch of its clinical research division...
Africa Healthcare Network names Matt Williams as new CEO, as Co-Founder Nikhil Pereira Transitions to Executive Chairman
July 01, 2022 01:00 ET
|
Africa Healthcare Network
NAIROBI, Kenya, July 01, 2022 (GLOBE NEWSWIRE) -- Africa Healthcare Network (“AHN”), East Africa’s largest kidney care and dialysis provider across Kenya, Tanzania and Rwanda, today announced that...
CHF Solutions and RenalSense Enter Distribution Partnership to Offer Ultrafiltration and Real-Time Renal Diagnostics
July 08, 2020 09:25 ET
|
CHF Solutions, Inc.
EDEN PRAIRIE, Minn., July 08, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) and RenalSense, Ltd., today announced the signing of a distribution agreement to offer complementary solutions for...
Proteon Therapeutics Announces Third Quarter 2019 Financial Results
October 31, 2019 17:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (“Proteon” or the “Company”) (Nasdaq: PRTO), a company that has historically focused on the development of novel,...
Proteon Therapeutics and ArTara Therapeutics Agree to Combine
September 23, 2019 16:20 ET
|
Proteon Therapeutics, Inc.
Transaction to Create NASDAQ-Listed Rare and Specialty Disease Therapeutic Company Focused on Immunology and Metabolic Disorders $42.5M Concurrent Financing to be Led by a Syndicate of Healthcare...
Proteon Therapeutics Announces Second Quarter 2019 Financial Results
August 07, 2019 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company that has historically focused on the development of novel, first-in-class pharmaceuticals to...
Worldwide Stent Market value worth $16 billion by 2025: Global Market Insights, Inc.
June 10, 2019 04:42 ET
|
Global Market Insights, Inc
Selbyville, Delaware, June 10, 2019 (GLOBE NEWSWIRE) -- Bioresorbable stent market will grow at 7.8% over the projected period. Bioresorbable stents get absorbed in the body after serving its...
Proteon Therapeutics Announces First Quarter 2019 Financial Results
May 08, 2019 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics Announces Review of Potential Strategic Transactions
April 15, 2019 16:30 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., April 15, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...